Polaryx Therapeutics, Inc. (PLYX)
1.61
+0.01
(+0.62%)
USD |
NASDAQ |
Nov 18, 16:00
1.61
0.00 (0.00%)
After-Hours: 20:00
Polaryx Therapeutics Total Liabilities (Quarterly) : 0.999M for Sept. 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.999M |
| June 30, 2026 | 0.873M |
| March 31, 2026 | 1.014M |
| December 31, 2025 | 0.855M |
| Date | Value |
|---|---|
| September 30, 2025 | 0.682M |
| June 30, 2025 | 0.296M |
| March 31, 2025 | 0.185M |
| December 31, 2024 | 0.756M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | 4.098M |
| CNBX Pharmaceuticals, Inc. | 2.672M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 93.70M |
| Fulcrum Therapeutics, Inc. | 8.784M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 8.61M |
| Shareholders Equity (Quarterly) | 7.611M |
| Current Ratio | 8.619 |